- 現金殖利率: 8.59%、總殖利率: 8.59%、5年平均現金配發率: 89.72%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 4.43 | 32.24 | 4.00 | 28.62 | 0.00 | 0 | 90.29 | -2.74 | 0.00 | 0 | 90.29 | -2.74 |
| 2024 (4) | 3.35 | 23.62 | 3.11 | 13.92 | 0.00 | 0 | 92.84 | -7.84 | 0.00 | 0 | 92.84 | -7.84 |
| 2023 (3) | 2.71 | 0.37 | 2.73 | 30.0 | 0.00 | 0 | 100.74 | 29.52 | 0.00 | 0 | 100.74 | 29.52 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 1.09 | -1.8 | 10.1 | 0.52 | 48.57 | -26.76 | 1.09 | -75.72 | 10.1 |
| 25Q4 (7) | 1.11 | -30.62 | -23.97 | 0.35 | -14.63 | -59.3 | 4.49 | 32.84 | 32.45 |
| 25Q3 (6) | 1.60 | 100.0 | 213.73 | 0.41 | -33.87 | -28.07 | 3.38 | 88.83 | 75.13 |
| 25Q2 (5) | 0.80 | -19.19 | 63.27 | 0.62 | -12.68 | 675.0 | 1.79 | 80.81 | 25.17 |
| 25Q1 (4) | 0.99 | -32.19 | 0.0 | 0.71 | -17.44 | 0.0 | 0.99 | -70.8 | 0.0 |
| 24Q4 (3) | 1.46 | 186.27 | 0.0 | 0.86 | 50.88 | 0.0 | 3.39 | 75.65 | 0.0 |
| 24Q3 (2) | 0.51 | 4.08 | 0.0 | 0.57 | 612.5 | 0.0 | 1.93 | 34.97 | 0.0 |
| 24Q2 (1) | 0.49 | 0.0 | 0.0 | 0.08 | 0.0 | 0.0 | 1.43 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/6 | 2.57 | 2.56 | -2.26 | 15.89 | -0.95 | 7.65 | N/A | - | ||
| 2026/5 | 2.51 | -2.45 | -4.18 | 13.31 | -0.7 | 7.9 | N/A | - | ||
| 2026/4 | 2.57 | -8.91 | -1.48 | 10.8 | 0.14 | 8.02 | N/A | - | ||
| 2026/3 | 2.82 | 7.66 | 4.8 | 8.23 | 0.65 | 8.23 | 0.44 | - | ||
| 2026/2 | 2.62 | -5.85 | 0.55 | 5.41 | -1.37 | 8.06 | 0.45 | - | ||
| 2026/1 | 2.79 | 4.98 | -3.13 | 2.79 | -3.13 | 7.87 | 0.46 | - | ||
| 2025/12 | 2.65 | 9.31 | 1.56 | 31.88 | 9.69 | 7.7 | 0.6 | - | ||
| 2025/11 | 2.43 | -7.19 | -1.98 | 29.22 | 10.49 | 7.64 | 0.6 | - | ||
| 2025/10 | 2.62 | 0.72 | -1.47 | 26.8 | 11.78 | 7.94 | 0.58 | - | ||
| 2025/9 | 2.6 | -4.66 | 1.16 | 24.18 | 13.43 | 8.14 | 0.37 | - | ||
| 2025/8 | 2.72 | -3.35 | 9.75 | 21.58 | 15.11 | 8.18 | 0.37 | - | ||
| 2025/7 | 2.82 | 7.05 | 21.24 | 18.86 | 15.93 | 8.07 | 0.37 | - | ||
| 2025/6 | 2.63 | 0.54 | 12.94 | 16.04 | 15.04 | 7.86 | 0.52 | - | ||
| 2025/5 | 2.62 | 0.29 | 11.99 | 13.41 | 15.46 | 7.92 | 0.52 | - | ||
| 2025/4 | 2.61 | -3.1 | 15.01 | 10.79 | 16.34 | 7.91 | 0.52 | - | ||
| 2025/3 | 2.69 | 3.29 | 10.03 | 8.18 | 16.77 | 8.18 | 0.51 | - | ||
| 2025/2 | 2.61 | -9.3 | 21.62 | 5.48 | 20.39 | 8.1 | 0.52 | - | ||
| 2025/1 | 2.88 | 10.07 | 19.29 | 2.88 | 19.29 | 7.97 | 0.52 | - | ||
| 2024/12 | 2.61 | 5.49 | 25.04 | 29.06 | 28.4 | 7.74 | 0.69 | - | ||
| 2024/11 | 2.48 | -6.71 | 20.02 | 26.45 | 28.75 | 7.7 | 0.69 | - | ||
| 2024/10 | 2.65 | 3.42 | 30.44 | 23.97 | 29.72 | 7.7 | 0.69 | - | ||
| 2024/9 | 2.57 | 3.42 | 26.61 | 21.32 | 29.63 | 7.37 | 0.45 | - | ||
| 2024/8 | 2.48 | 6.75 | 28.97 | 18.75 | 30.06 | 7.14 | 0.46 | - | ||
| 2024/7 | 2.32 | -0.26 | 19.22 | 16.27 | 30.22 | 6.99 | 0.47 | - | ||
| 2024/6 | 2.33 | -0.29 | 35.44 | 13.94 | 32.26 | 6.94 | 0.36 | - | ||
| 2024/5 | 2.34 | 2.99 | 32.98 | 11.61 | 31.64 | 7.06 | 0.36 | - | ||
| 2024/4 | 2.27 | -7.29 | 39.59 | 9.27 | 31.3 | 6.86 | 0.37 | - | ||
| 2024/3 | 2.45 | 14.18 | 37.52 | 7.0 | 28.82 | 7.0 | N/A | - | ||
| 2024/2 | 2.14 | -11.04 | 24.63 | 4.56 | 24.59 | 6.64 | N/A | - | ||
| 2024/1 | 2.41 | 15.37 | 24.56 | 2.41 | 24.56 | 6.56 | N/A | - | ||
| 2023/12 | 2.09 | 1.26 | 27.04 | 22.63 | -8.58 | 6.19 | N/A | - | ||
| 2023/11 | 2.06 | 1.38 | 26.12 | 20.54 | -11.11 | 6.13 | N/A | - | ||
| 2023/10 | 2.04 | 0.38 | 26.44 | 18.48 | -13.95 | 5.99 | N/A | - | ||
| 2023/9 | 2.03 | 5.35 | 33.05 | 16.44 | -17.22 | 5.9 | N/A | - | ||
| 2023/8 | 1.92 | -1.3 | 26.55 | 14.42 | -21.4 | 5.6 | N/A | - | ||
| 2023/7 | 1.95 | 13.29 | 27.21 | 12.49 | -25.74 | 5.43 | N/A | - | ||
| 2023/6 | 1.72 | -2.1 | -4.88 | 10.54 | -31.05 | 5.11 | N/A | - | ||
| 2023/5 | 1.76 | 8.12 | -54.83 | 8.82 | -34.56 | 5.16 | N/A | 主要係子公司業績較去年同期減少，因去年同期正逢國內疫情延燒，子公司搶進快篩試劑通路，帶動去年當期業績大幅成長。 | ||
| 2023/4 | 1.63 | -8.67 | -11.63 | 7.06 | -26.33 | 5.13 | N/A | - | ||
| 2023/3 | 1.78 | 3.48 | -31.31 | 5.44 | -29.82 | 5.44 | N/A | - | ||
| 2023/2 | 1.72 | -11.09 | -28.36 | 3.66 | -29.06 | 5.3 | N/A | - | ||
| 2023/1 | 1.94 | 17.68 | -29.67 | 1.94 | -29.67 | 5.22 | N/A | - | ||
| 2022/12 | 1.64 | 0.53 | -33.23 | 24.76 | -16.84 | 4.89 | N/A | - | ||
| 2022/11 | 1.64 | 1.64 | -35.19 | 23.11 | -15.36 | 4.77 | N/A | - | ||
| 2022/10 | 1.61 | 5.62 | -38.32 | 21.48 | -13.34 | 4.65 | N/A | - | ||
| 2022/9 | 1.52 | 0.2 | -33.34 | 19.87 | -10.4 | 4.58 | N/A | - | ||
| 2022/8 | 1.52 | -0.79 | -43.54 | 18.34 | -7.76 | 4.86 | N/A | - | ||
| 2022/7 | 1.53 | -15.29 | -41.01 | 16.82 | -2.15 | 7.23 | N/A | - | ||
| 2022/6 | 1.81 | -53.51 | -23.01 | 15.29 | 4.75 | 7.54 | N/A | - | ||
| 2022/5 | 3.89 | 111.55 | 57.32 | 13.48 | 10.09 | 8.33 | N/A | 主要係子公司於今年國內疫情延燒期間積極搶進快篩試劑市場通路佈局，帶動流通事業的業績大幅成長。 | ||
| 2022/4 | 1.84 | -29.01 | -28.5 | 9.59 | -1.87 | 6.83 | N/A | - | ||
| 2022/3 | 2.59 | 7.93 | 4.5 | 7.75 | 7.65 | 7.75 | N/A | - | ||
| 2022/2 | 2.4 | -12.72 | 5.96 | 5.15 | 9.3 | 7.62 | N/A | - | ||
| 2022/1 | 2.75 | 11.72 | 12.4 | 2.75 | 12.4 | 7.74 | N/A | - | ||
| 2021/12 | 2.46 | -2.41 | 7.52 | 29.77 | -16.43 | 7.6 | N/A | - | ||
| 2021/11 | 2.52 | -3.25 | -19.27 | 27.31 | -18.08 | 7.42 | N/A | - | ||
| 2021/10 | 2.61 | 14.14 | -1.15 | 24.78 | -17.95 | 7.59 | N/A | - | ||
| 2021/9 | 2.29 | -15.12 | -32.73 | 22.17 | -19.56 | 7.58 | N/A | - | ||
| 2021/8 | 2.69 | 3.65 | -26.66 | 19.89 | -17.71 | 0.0 | N/A | - | ||
| 2021/7 | 2.6 | 10.56 | -27.02 | 17.19 | -16.11 | 0.0 | N/A | - |